Akero Therapeutics Inc Stock
Price
Target price
€21.89
€21.89
0.460%
0.1
0.460%
€38.62
28.06.24 / Tradegate
WKN: A2PLNP / Symbol: AKRO / Name: Akero Therapeutics / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction
Akero Therapeutics Inc Stock
Akero Therapeutics Inc gained 0.460% compared to yesterday.
Akero Therapeutics Inc is currently one of the favorites of our community with 18 Buy predictions and no Sell predictions.
As a result the target price of 38 € shows a very positive potential of 73.6% compared to the current price of 21.89 € for Akero Therapeutics Inc.
For the coming years our community has positive and negative things to say abot the Akero Therapeutics Inc stock. Criterium "Revenue growth" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Akero Therapeutics Inc in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Akero Therapeutics Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Akero Therapeutics Inc | 0.460% | 0.969% | 24.023% | -46.348% | 0.413% | - | - |
| Ardelyx Inc. | 0.220% | -19.513% | -22.472% | 60.393% | -15.363% | -26.985% | - |
| Evolus Inc | 2.620% | -1.546% | -16.957% | 48.062% | 5.525% | -9.048% | - |
| Brainstorm Cell | -4.330% | -7.439% | -28.031% | -82.514% | 43.142% | -89.565% | -90.957% |
Comments
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Show more
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
Show more
Ratings data for AKRO provided by MarketBeat
